Japanese trading and pharmaceutical company Kowa announced on Monday (Jan. 31) that ivermectin showed an “antiviral effect” against Omicron and other variants of SARS-CoV-2 in joint non-clinical research.

The firm has been working with Kitasato University, a medical university in Tokyo, on testing the efficacy and safety of ivermectin 0.3-0.4 mg/kg orally administered once daily for 3 days will be evaluated in patients with mild COVID-19 using a randomized, double-blind, parallel-group comparative method with placebo as a control.
This is getting ridiculous. They literally are now censoring a peer reviewed paper on ivermectin. https://t.co/msJ3uZB9n3
— Trudy Seivwright MD (@SeivwrightTrudy) January 25, 2022
The clinical trials are still ongoing.